Bixiye
QP97-21 MHCP Pharmacy Benefit Exclusion for Asparlas™, Khapzory™, Nulojix®, Oncaspar® and Susvimo™
Taariikhda uu dhaqangalayo Barnaamijka: Des 08, 2021
Dukumentiyadda & Foomamka Natiijooyinka
Soo bandhiga 1451 - 1460 ee natiijooyinka 3613
Bixiye
QP98-21 Commercial Pharmacy Benefit Exclusion for Nulojix® and Susvimo™
Taariikhda uu dhaqangalayo Barnaamijka: Des 08, 2021
Bixiye
QP99-21 Blue Cross and Blue Shield of Minnesota Collaboration with VillageHealth
Taariikhda uu dhaqangalayo Barnaamijka: Des 08, 2021
Bixiye
QP100-21 Checks to be Sent for Unpaid Prompt Pay Penalties
Taariikhda uu dhaqangalayo Barnaamijka: Des 08, 2021
Bixiye
QP101-21 Commercial Pharmacy Benefit Update – Revised Drug-Related Prior Authorization (PA) Requirement Notification – Effective February 1, 2022
Taariikhda uu dhaqangalayo Barnaamijka: Des 08, 2021
Bixiye
2021 December Provider Press
Taariikhda uu dhaqangalayo Barnaamijka: Des 03, 2021
Bixiye
P61R1-21 Update: Evaluation and Management Reimbursement Changes
Taariikhda uu dhaqangalayo Barnaamijka: Des 01, 2021
Bixiye
P68R1-21 Update: eviCore Healthcare Specialty Utilization Management (UM) Program - Laboratory Management Clinical Guideline Updates
Taariikhda uu dhaqangalayo Barnaamijka: Des 01, 2021